Carlsmed appoints Jenifer Kamocsay as chief legal officer

CARLSBAD, Calif. - Carlsmed, Inc. (NASDAQ:CARL), a medical technology company focused on personalized spine surgery solutions with a market capitalization of $363 million, announced Monday the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. According to InvestingPro data, the company maintains a Fair financial health score, with liquid assets exceeding short-term obligations.

Kamocsay brings over 20 years of corporate legal experience to the role, having previously served as in-house counsel at Akoya Biosciences, Rubius Therapeutics, and Progress Software Corporation.

"We are pleased to welcome Jennifer to the Carlsmed leadership team as we strengthen our organization and strategically expand our leadership team following our IPO," said Mike Cordonnier, Chairman and CEO of Carlsmed.

In her new position, Kamocsay will serve as legal counsel for the company and oversee compliance and corporate governance matters.

Prior to joining Carlsmed, she was General Counsel and Corporate Secretary at Rubius Therapeutics, where she managed all legal affairs. She also served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, handling corporate, securities law, and M&A initiatives.

Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, providing counsel to biotechnology and pharmaceutical clients. She holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law.

Carlsmed, which is preparing for its cervical commercial launch, completed its initial public offering earlier this year. While operating with a moderate level of debt, analysts do not anticipate profitability this year, according to InvestingPro data. The company stated in its press release that it expects to launch its aprevo cervical product in the United States in 2026. For deeper insights into Carlsmed’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Carlsmed, Inc. has reported a substantial increase in its Q2 2025 revenue, achieving a 99% year-over-year growth to $12.1 million. This financial performance has been a point of optimism for investors and analysts alike. Goldman Sachs has reiterated its Buy rating for Carlsmed, maintaining a $19.00 price target, citing confidence in the company’s growth outlook and potential for further upside. The investment bank has also upheld its high revenue estimates for the company. Additionally, Carlsmed has been included in the Russell 2000 Index following its Q3 IPO, which took place in July. This inclusion is part of a planned addition of select companies that recently completed initial public offerings. These developments highlight Carlsmed’s strengthening position in the market and its potential for continued growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.